Literature DB >> 17024659

Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry.

Paolo Guidetti1, Gloria E Hoffman, Miguel Melendez-Ferro, Edson X Albuquerque, Robert Schwarcz.   

Abstract

Kynurenic acid (KYNA), a metabolite of the kynurenine pathway of tryptophan degradation, is a neuroinhibitory agent present in the mammalian brain. Endogenous KYNA preferentially affects the alpha7 nicotinic acetylcholine (alpha7nACh) receptor and, possibly, the glycine co-agonist (glycineB) site of the NMDA receptor. Functionally relevant fluctuations in brain KYNA occur under both physiological and pathological conditions, affecting cholinergic and glutamatergic neurotransmission. Kynurenine aminotransferase II (KAT II), the major biosynthetic enzyme of KYNA in the rat brain, catalyzes the irreversible formation of KYNA from its immediate bioprecursor, kynurenine. We now purified rat kidney KAT II to homogeneity, generated a polyclonal rabbit anti-rat KAT II antibody, and purified the antibody using routine biochemical methods. The antibody selectively recognized KAT II by Western blot analysis and in immunotitration experiments. Used for immunocytochemistry, the antibody revealed discrete, specific staining of KAT II-positive astrocyte-like cells throughout the adult rat brain. The presence of KAT II in astrocytes was confirmed by double fluorescence immunostaining with an antibody against the astrocyte-specific marker glial fibrillary acidic protein (GFAP). No specific labeling was detected in neurons or microglia. However, KAT II-positive astrocytes were intimately associated with select neuron populations, supporting a neuromodulatory role of KYNA. Intense staining was frequently seen around brain capillaries, with astrocytic end feet contacting the capillary wall. This may explain the rapid access of blood-derived kynurenine to KAT II-containing astrocytes. The new anti-KAT II antibody should be useful in the further elucidation of the presumed role of KYNA in brain physiology and pathology. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17024659     DOI: 10.1002/glia.20432

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  75 in total

1.  Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain.

Authors:  Manickavasagom Alkondon; Edna F R Pereira; Howard M Eisenberg; Yasushi Kajii; Robert Schwarcz; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2011-01-26       Impact factor: 4.030

2.  Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

Authors:  Kathleen S Alexander; Hui-Qiu Wu; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

3.  Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.

Authors:  Ana Pocivavsek; Hui-Qiu Wu; Greg I Elmer; John P Bruno; Robert Schwarcz
Journal:  Eur J Neurosci       Date:  2012-04-20       Impact factor: 3.386

4.  Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior.

Authors:  Michelle C Potter; Greg I Elmer; Richard Bergeron; Edson X Albuquerque; Paolo Guidetti; Hui-Qiu Wu; Robert Schwarcz
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

5.  Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor.

Authors:  Hui-Qiu Wu; Masahiro Okuyama; Yasushi Kajii; Ana Pocivavsek; John P Bruno; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2014-03       Impact factor: 9.306

6.  Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders.

Authors:  Alexei Verkhratsky; Vladimir Parpura
Journal:  Neurobiol Dis       Date:  2015-04-03       Impact factor: 5.996

7.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

Review 8.  Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges.

Authors:  Edson X Albuquerque; Robert Schwarcz
Journal:  Biochem Pharmacol       Date:  2012-12-25       Impact factor: 5.858

9.  Exposure to elevated embryonic kynurenine in rats: Sex-dependent learning and memory impairments in adult offspring.

Authors:  Silas A Buck; Annalisa M Baratta; Ana Pocivavsek
Journal:  Neurobiol Learn Mem       Date:  2020-07-30       Impact factor: 2.877

10.  Expression of tryptophan 2,3-dioxygenase in mature granule cells of the adult mouse dentate gyrus.

Authors:  Koji Ohira; Hideo Hagihara; Keiko Toyama; Keizo Takao; Masaaki Kanai; Hiroshi Funakoshi; Toshikazu Nakamura; Tsuyoshi Miyakawa
Journal:  Mol Brain       Date:  2010-09-05       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.